Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient

Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient

Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe...

Full description

Bibliographic Details
Main Authors: Bhanvi Ramchandani, Faryal Sardar Mirza
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Bone Reports
Subjects:
Post-menopausal osteoporosis
Romosozumab
Primary biliary cholangitis
Fractures
Monoclonal antibodies
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187224000032

Internet

http://www.sciencedirect.com/science/article/pii/S2352187224000032

Similar Items